Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

DURAMED RESEARCH

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Multicenter Study to Evaluate the Effects of a 91-day Oral Contraceptive on Bone Mineral Density in Adolescent Females

Phase 2

Completed

Conditions: Bone Mineral Density

Interventions: Drug: 91-day Levonorgestrel Oral Contraceptive
Drug: 28-day Levonorgestrel Oral Contraceptive

First Posted Date: 2009-06-19

Last Posted Date: 2014-10-22

Lead Sponsor: Duramed Research

Target Recruit Count: 1361

Registration Number: NCT00924560

Locations: 🇺🇸
Teva Investigational Site 007, Phoenix, Arizona, United States
🇺🇸
Teva Investigational Site 018, Phoenix, Arizona, United States
🇺🇸
Teva Investigational Site 005, Tucson, Arizona, United States

and more 43 locations

A Safety Extension Study of DR-OXY-301

Phase 3

Completed

Conditions: Overactive Bladder

Interventions: Drug: Oxybutinyn Vaginal Ring 4mg
Drug: Oxybutinyn Vaginal Ring 6mg

First Posted Date: 2008-10-31

Last Posted Date: 2023-03-16

Lead Sponsor: Duramed Research

Target Recruit Count: 240

Registration Number: NCT00782769

Locations: 🇺🇸
Duramed Investigational Site, Tacoma, Washington, United States

A Multicenter Study to Evaluate the Efficacy of a 91-Day Extended Cycle Oral Contraceptive for Menstrually-Related Migraine Headaches

Phase 2

Completed

Conditions: Migraine

Interventions: Drug: 91-day Levonorgestrel Oral Contraceptive
Drug: Placebo

First Posted Date: 2008-10-29

Last Posted Date: 2017-02-06

Lead Sponsor: Duramed Research

Target Recruit Count: 109

Registration Number: NCT00781456

Locations: 🇺🇸
Teva Investigational Site, Houston, Texas, United States
🇺🇸
Duramed Investigational Site, Seattle, Washington, United States

Emergency Contraception Actual Use Study

Phase 3

Completed

Conditions: Emergency Contraception

Interventions: Drug: DR-104

First Posted Date: 2008-10-22

Last Posted Date: 2012-10-18

Lead Sponsor: Duramed Research

Target Recruit Count: 343

Registration Number: NCT00777556

Locations: 🇺🇸
Duramed Research Investigational Site, Philadelphia, Pennsylvania, United States
🇺🇸
Teva Investigational Site, Pittsburgh, Pennsylvania, United States

A Clinical Trial to Evaluate the Efficacy and Safety of DR-3001 in Women With Overactive Bladder

Phase 3

Completed

Conditions: Overactive Bladder

Interventions: Drug: DR-3001
Drug: Placebo

First Posted Date: 2008-05-28

Last Posted Date: 2016-07-20

Lead Sponsor: Duramed Research

Target Recruit Count: 1104

Registration Number: NCT00685113

Locations: 🇨🇦
Duramed Investigational Site, Thunder Bay, Ontario, Canada
🇺🇸
Duramed Investigation Site, Decatur, Georgia, United States
🇨🇦
Duramed Investigatinal Site, Vancouver, British Columbia, Canada

A Clinical Trial to Evaluate the Efficacy and Safety of DR-2011 for In Vitro Fertilization

Phase 3

Completed

Conditions: Infertility

Interventions: Drug: DR-2011
Drug: Crinone 8%

First Posted Date: 2008-02-14

Last Posted Date: 2013-09-13

Lead Sponsor: Duramed Research

Target Recruit Count: 1297

Registration Number: NCT00615251

Locations: 🇺🇸
Duramed Investigational Site, Norfolk, Virginia, United States

Study to Evaluate the Effects of Synthetic Conjugated Estrogens, B (SCE-B) on Nocturnal Vasomotor Symptoms in Postmenopausal Women

Phase 4

Completed

Conditions: Nocturnal Vasomotor Symptoms

Interventions: Drug: SCE-B
Drug: Placebo

First Posted Date: 2008-01-14

Last Posted Date: 2013-07-19

Lead Sponsor: Duramed Research

Target Recruit Count: 157

Registration Number: NCT00592839

Locations: 🇺🇸
Duramed Investigational Site, San Antonio, Texas, United States

A Study to Evaluate Bleeding Patterns With Three Different Doses of DR-1031 Compared to Seasonale

Phase 2

Completed

Conditions: Breakthrough Bleeding

Interventions: Drug: Seasonale®
Drug: DR-1031
Drug: Portia®

First Posted Date: 2006-11-01

Last Posted Date: 2013-07-26

Lead Sponsor: Duramed Research

Target Recruit Count: 567

Registration Number: NCT00394771

Locations: 🇺🇸
Duramed Investigational Site, Williston, Vermont, United States

A Clinical Trial to Evaluate the Safety, Efficacy, and Immunogenicity of DR-5001

Phase 3

Completed

Conditions: Respiratory Tract Diseases

Interventions: Biological: DR-5001
Other: Placebo

First Posted Date: 2006-09-29

Last Posted Date: 2017-04-10

Lead Sponsor: Duramed Research

Target Recruit Count: 4040

Registration Number: NCT00382408

Locations: 🇺🇸
Duramed Investigational Site, Fort Jackson, South Carolina, United States

Open-Label Study to Evaluate the Safety and Efficacy of a Low-Dose 28-Day Oral Contraceptive

Phase 3

Completed

Conditions: Contraception

Interventions: Drug: DR-1021

First Posted Date: 2006-08-10

Last Posted Date: 2013-08-21

Lead Sponsor: Duramed Research

Target Recruit Count: 1347

Registration Number: NCT00362479

Locations: 🇺🇸
Duramed Investigational Site, Tacoma, Washington, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy